This is therefore a comparing of the risk, analyst recommendations, profitability, institutional ownership, dividends, earnings and valuation in Protagonist Therapeutics Inc. (NASDAQ:PTGX) and Biohaven Pharmaceutical Holding Company Ltd. (NYSE:BHVN). The two are both Biotechnology companies that compete with one another.

Earnings & Valuation

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Protagonist Therapeutics Inc.	30.93M	9.08	38.92M	-1.30	0.00
Biohaven Pharmaceutical Holding Company Ltd.	N/A	0.00	240.92M	-5.61	0.00

We can see in table 1 the earnings per share (EPS), top-line revenue and valuation of Protagonist Therapeutics Inc. and Biohaven Pharmaceutical Holding Company Ltd.

Profitability

Table 2 represents Protagonist Therapeutics Inc. (NASDAQ:PTGX) and Biohaven Pharmaceutical Holding Company Ltd. (NYSE:BHVN)’s return on assets, net margins and return on equity.

	Net Margins	Return on Equity	Return on Assets
Protagonist Therapeutics Inc.	-125.83%	-24.1%	-18.8%
Biohaven Pharmaceutical Holding Company Ltd.	0.00%	-201%	-120.6%

Liquidity

The Current Ratio and a Quick Ratio of Protagonist Therapeutics Inc. are 6.1 and 6.1. Competitively, Biohaven Pharmaceutical Holding Company Ltd. has 12 and 12 for Current and Quick Ratio. Biohaven Pharmaceutical Holding Company Ltd.’s better ability to pay short and long-term obligations than Protagonist Therapeutics Inc.

Analyst Ratings

Protagonist Therapeutics Inc. and Biohaven Pharmaceutical Holding Company Ltd. Recommendations and Ratings are available in the next table.

	Sell Ratings	Hold Ratings	Buy Ratings	Rating Score
Protagonist Therapeutics Inc.	0	0	1	3.00
Biohaven Pharmaceutical Holding Company Ltd.	0	0	0	0.00

Protagonist Therapeutics Inc. has a 41.31% upside potential and an average price target of $17.

Institutional and Insider Ownership

Protagonist Therapeutics Inc. and Biohaven Pharmaceutical Holding Company Ltd. has shares held by institutional investors as follows: 87% and 91.4%. About 1.8% of Protagonist Therapeutics Inc.’s share are held by insiders. Competitively, Biohaven Pharmaceutical Holding Company Ltd. has 1.1% of it’s share held by insiders.

Performance

Here are the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

	Performance (W)	Performance (M)	Performance (Q)	Performance (HY)	Performance (Y)	Performance (YTD)
Protagonist Therapeutics Inc.	8.89%	8.22%	40%	-11.27%	-49.34%	31.05%
Biohaven Pharmaceutical Holding Company Ltd.	3.76%	23.81%	50.91%	27.74%	45.51%	27.53%

For the past year Protagonist Therapeutics Inc.’s stock price has bigger growth than Biohaven Pharmaceutical Holding Company Ltd.

Summary

Protagonist Therapeutics Inc. beats Biohaven Pharmaceutical Holding Company Ltd. on 8 of the 10 factors.

Protagonist Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing peptide-based chemical entities to address various unmet medical needs. It primarily focuses on developing oral peptide drugs. The companyÂ’s lead product candidates include PTG-100, an oral alpha-4-beta-7 integrin-specific antagonist that is in phase II clinical trial for the treatment of inflammatory bowel disease (IBD); and PTG-200, an interleukin-23 receptor specific antagonist, which is under pre-clinical development stage for the treatment of IBD. It is also developing PTG-300, an injectable hepcidin mimetic peptide that is in pre-clinical development stage to treat iron overload disorders, such as b-Thalassemia, hereditary hemochromatosis, and sickle cell disease. The company was founded in 2006 and is headquartered in Milpitas, California.

Biohaven Pharmaceutical Holding Company Ltd., a clinical-stage biopharmaceutical company, develops product candidates to treat neurological diseases, including rare disorders. Its advanced product candidate includes rimegepant, which is intended to initiate two Phase III clinical trials for the acute treatment of migraine; and trigriluzole, which is in a Phase II/III clinical trial used for the treatment of ataxias with an initial focus on spinocerebellar ataxia. The company also develops BHV-3500 for the prevention of chronic and episodic migraine; BHV-0223 for the treatment of amyotrophic lateral sclerosis, a neurodegenerative disease that affects nerve cells in the brain and spinal cord; and BHV-5000 for the treatment of symptoms associated with Rett syndrome, such as breathing irregularities. Biohaven Pharmaceutical Holding Company Ltd. was founded in 2013 and is based in New Haven, Connecticut. Biohaven Pharmaceutical Holding Company Ltd. is a subsidiary of Portage Biotech Inc.